25 result(s) displayed (1 - 25 of 29):
It makes sense that GlaxoSmithKline plc (NYSE:GSK) would emerge as the front-runner to acquire a stake in Indian drug giant Dr. Reddy's Laboratories Ltd. (NYSE:RDY). Citing people familiar with the matter, Reuters says that while nothing is finalized, one possibility is that Glaxo will take a 20% stake in Dr....
Posted on October 8, 2009 9:12 AM
Pharma giant GlaxoSmithKline plc (NYSE:GSK) has done a dozen or so acquisitions and partnerships since Andrew Witty took over as CEO in May of 2008, and it would like to do more. But GSK R&D chief Moncef Slaoui (pictured) complains in an interview with Bloomberg published Friday that "desperate" rivals...
Posted on September 25, 2009 9:26 AM
GlaxoSmithKline plc's (NYSE:GSK) latest deal, a collaboration with U.K. biotech firm Vernalis plc valued at up to $200 million, is one of a flurry of alliances in the oncology sector in the past few months. We have a pretty comprehensive list of the major deals here. GSK and Vernalis...
Posted on August 6, 2009 1:46 PM
Amgen Inc. (NASDAQ:AMGN) late Monday said it would tap GlaxoSmithKline plc (NYSE:GSK) for help selling a promising osteoporosis treatment outside the U.S. The sale of denosumab (or d-mab) rights was widely expected and one of several high-profile rights deals (The Deal Pipeline subscription required) on the horizon.Glaxo will pay $120...
Posted on July 28, 2009 8:44 AM
In the long winding road from "secret merger talks" to deal completion, bankers, lawyers and corporate dealmakers alike breathe easier when their hard work is met with regulatory and shareholder approvals along the way. Collecting fees is also a source of comfort. Sure, they get money from retainer and reimbursement...
Posted on July 17, 2009 3:01 PM
OncoMed Pharmaceuticals Inc. has appointed Sunil Patel to the new position of senior vice president of corporate development. OncoMed is a clinical-stage company that develops therapeutics targeting cancer stem cells. Patel joins from BiPar Sciences, which was acquired by Sanofi-Aventis (NYSE:SNY) in April. As BiPar's VP of corporate development, Patel...
Posted on July 9, 2009 8:50 AM
After watching his rivals consolidate and generic competition squeeze the company's earnings, GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty started allying to expand in emerging markets and shift money from pharmaceuticals into vaccines and consumer businesses.The latest deal is a revenue-sharing agreement with India's Dr. Reddy's Laboratories Ltd. (NYSE:RDY),...
Posted on June 16, 2009 12:52 PM
In an interesting play, four rival drug giants are using their venture capital arms to back a company they think has come up with a major new class of therapeutics. Biotech company Aileron Therapeutics received financing from GlaxoSmithKline plc (NYSE:GSK), Novartis AG (NYSE:NVS), Roche Holding AG (SWX:ROG) and Eli Lilly...
Posted on June 8, 2009 3:30 PM
Combining traditional pharma R&D with the biotech version -- high risk, high reward, highly creative and often fueled with some good jolts of venture capital -- seems to be the preferred solution to the productivity problems that ail the Big Pharma companies. But how do you go about it?The industry...
Posted on June 3, 2009 12:50 PM
Pfizer Inc.'s (NYSE:PFE) $68 billion acquisition of Wyeth (NYSE:WYE) and Merck & Co.'s (NYSE:MRK) $41 billion bid for Schering Plough Corp. (NYSE:SGP) sparked fresh speculation on whether pharma megamergers create value and whether industry consolidation would continue. We've done our share of analysis. Recently, Baz Hiralal posted this solid roundup...
Posted on June 2, 2009 2:46 PM
How's this for a sign of the times: One of the most innovative drug industry deals of the year involves the biggest firm of them all, Pfizer Inc. (NYSE:PFE), but it isn't its $68 billion takeover of Wyeth. Instead, the pundits at Windhover Research's In Vivo blog say Pfizer is...
Posted on May 27, 2009 3:00 PM
Recent deals done by GlaxoSmithKline plc (NYSE:GSK), Electricitie de France SA and Fiat SpA serve as prime examples of the extreme dealmaking that was talked about at October's Corporate Dealmaker Forum. That was about the time the recession was settling in for the long haul.A Reuters article highlighted these companies...
Posted on May 22, 2009 9:50 AM
As its first-quarter results were hammered by generic competition, GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty's game plan is to stay away from megamergers, expand in emerging markets and shift money from pharmaceuticals into vaccines and consumer businesses as more blockbuster drugs face generic competition. One such drug is its...
Posted on May 6, 2009 9:03 AM
London-based pharma market intelligence report publisher URCH Publishing, which itself recently acquired pharma research firm Spectra Intelligence, is making predictions about who among the top 10 pharmas will follow in the footsteps of the sector's three biggest deals this year, with Bristol-Myers Squibb Co. (NYSE:BMY), Bayer AG and Novartis...
Posted on April 23, 2009 9:14 AM
Piramal Healthcare Ltd., the Indian generic drug maker, recently eyed by Sanofi-Aventis SA (NYSE:SNY) and possibly GlaxoSmithKline plc (NYSE:GSK), is looking to hire hundreds of people and acquire companies in Europe and North America. In December, Piramal spent $40 million on Minrad International Inc., a provider of generic inhalation anesthetics.Reuters...
Posted on April 22, 2009 8:14 AM
GlaxoSmithKline plc (NYSE:GSK) is acquiring the world's largest independent dermatology company, Stiefel Laboratories Inc., for up to $3.6 billion. So far most reports have focused on Glaxo CEO Andrew Witty's strategy, which includes staying away from megamergers, expanding in emerging markets and shifting money from pharmaceuticals into vaccines and...
Posted on April 20, 2009 5:39 PM
Merck & Co. (NYSE:MRK) is hoping to strengthen its pipeline and broaden its portfolio with its planned $41.1 billion acquisition of Schering-Plough Corp. (NYSE:SGP). But the megadeal hasn't distracted it from pursuing the kind of smaller licensing deals that have become an increasingly important tool for cost-conscious pharma giants. Merck...
Posted on April 9, 2009 8:03 AM
Eli Lilly & Co. (NYSE:LLY) CEO John Lechleiter (pictured) wants to stop the mega-merger madness. He told the Financial Times the recent big drug mergers are "driven more by weakness" and are short-term fixes that fail to address long-term productivity problems. He specifically rejected the idea of a combo with...
Posted on March 30, 2009 2:04 PM
News of pharma consolidation continued Thursday with various reports, including from The Wall Street Journal and Reuters, saying GlaxoSmithKline plc (NYSE:GSK) is in talks to acquire a minority stake in South African generic drugmaker Aspen Pharmacare Holdings Ltd. The Journal says Glaxo will likely buy 25% of Aspen, which has...
Posted on March 26, 2009 8:21 AM
GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty has said megamergers are a bad idea and that he likes being in consumer products (translation: look for bolt-on deals). More recently, at the Cowen & Co. healthcare conference in Boston, Witty (pictured) said Glaxo plans to shift money from its pharmaceuticals...
Posted on March 18, 2009 2:34 PM
The trend of merging pharmas continued Monday with Merck & Co. (NYSE:MRK) and Schering-Plough Corp. (NYSE:SGP) announcing they would merge in a cash-and-stock deal worth $41.1 billion. The deal makes Merck the No. 2 drugmaker in the U.S. So what does that mean for competitors like Bristol-Myers Squibb Co. and...
Posted on March 9, 2009 9:27 AM
Pharma industry experts (including ours, for Pipeline subscribers) will be weighing in on this over the course of the day -- and well beyond if the talks about Pfizer Inc. buying Wyeth, reported in The Wall Street Journal and Financial Times this morning, bear fruit.Meanwhile, a few quick thoughts on...
Posted on January 23, 2009 10:08 AM
Strategic alliances have always been an efficient mechanism for pharmaceutical companies to pursue development of multiple drugs. But as R&D costs skyrocket and the length of time required for regulatory approval lengthens, they're becoming an even more critical tool. On Wednesday, GlaxoSmithKline plc and Pfizer Inc. both announced new R&D partnerships....
Posted on December 18, 2008 10:18 AM
Big Pharmas are cutting costs; Bristol-Myers Squibb Co., Wyeth, Pfizer, Merck & Co., Schering-Plough Corp. and GlaxoSmithKline plc have all announced reductions in their U.S. sales forces. They're also worrying about life under the Democrats.Do they still want to replenish their pipelines with high-priced biotech drugs? James Greenwood, president and...
Posted on November 20, 2008 4:23 PM
Biotech giant Amgen Inc. wants to buy, and it has the money to do so. Bloomberg.com reported that Amgen has $9.76 billion in cash and marketable securities -- the healthcare sector's third-biggest cash hoard, behind only Pfizer Inc.'s $26.2 billion and Wyeth's $13.5 billion.A spokesman told Bloomberg that Amgen sees...
Posted on November 5, 2008 3:53 PM
1
2
Next
Movable Type search results powered by Fast Search
Juergen Lasowski
And the winners are...
